Date: 07/08/2014

Several months ago Galderma prepared a Qualitative Study of Lamellar Ichthyosis, with the assistance of some of the FIRST members.  As an update to their research, on July 1, Galderma announced that the FDA granted Orphan Drug Designation status for the company’s trifarotene molecule for the treatment of congenital ichthyosis. Follow the link to learn more.

Share This Page: